Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Spondyloarthropathy: interleukin 23 and disease modification.

Journal article

Sherlock JP. et al, (2015), Lancet, 385, 2017 - 2018

The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases

Journal article

Sherlock JP. et al, (2015), Current opinion in rheumatology, 27, 71 - 75

The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases.

Journal article

Sherlock JP. et al, (2015), Curr opin rheumatol, 27, 71 - 75

IL-23 in Health and Disease

Chapter

Sherlock JP. et al, (2014), Cytokine Frontiers, 179 - 198

The critical role of interleukin-23 in spondyloarthropathy

Journal article

Sherlock J. et al, (2014), Molecular immunology, 57, 38 - 43

The critical role of interleukin-23 in spondyloarthropathy.

Journal article

Sherlock JP. et al, (2014), Mol immunol, 57, 38 - 43

Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathy.

Journal article

Sherlock JP. and Cua DJ., (2013), Curr opin pharmacol, 13, 445 - 448

What can rheumatologists learn from translational cancer therapy?

Journal article

Sherlock JP. et al, (2013), Arthritis res ther, 15

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.

Journal article

Sherlock JP. et al, (2012), Nat med, 18, 1069 - 1076